Risk factors associated with loss to follow-up from tuberculosis treatment in Tajikistan: a case-control study

Jessica Wohlleben 1,2, Mavluda Makhmudova 3, Firuza Saidova 3, Shahnoza Azamova 4, Christina Mergenthaler 1,5 and Suzanne Verver 1,6,7*

Abstract

Background: There are very few studies on reasons for loss to follow-up from TB treatment in Central Asia. This study assessed risk factors for LTFU and compared their occurrence with successfully treated (ST) patients in Tajikistan.

Methods: This study took place in all TB facilities in the 19 districts with at least 5 TB patients registered as loss to follow-up (LTFU) from treatment. With a matched case control design we included all LTFU patients registered in the selected districts in 2011 and 2012 as cases, with ST patients from the same districts being controls. Data were copied from patient records and registers. Conditional logistic regressions were run to analyse associations between collected variables and LTFU as dependent variable.

Results: Three hundred cases were compared to 592 controls. Half of the cases had migrated or moved. In multivariate analysis, risk factors associated with increased LTFU were migration to another country (OR 10.6, 95% CI 6.12–18.4), moving within country (OR 11.0, 95% CI 3.50–34.9), having side effects of treatment (OR 3.67, 95% CI 1.68–8.00) and being previously treated for TB (OR 2.03, 95% CI 1.05–3.93). Medical staff also mentioned patient refusal, stigma and family problems as risk factors.

Conclusions: LTFU of TB patients in Tajikistan is largely a result of migration, and to a lesser extent associated with side-effects and previous treatment. There is a need to strengthen referral between health facilities within Tajikistan and with neighbouring countries and support patients with side effects and/or previous TB to prevent loss to follow-up from treatment.

Keywords: Default, Migration, Case-control study

Background

TB patients lost to follow-up (LTFU) are defined as “TB patients who did not start treatment or whose treatment was interrupted for two consecutive months or more” [1] and were previously called defaulters. LTFU patients are more likely to redevelop infectious active TB, and are at higher risk of developing MDR-TB [2].

Reasons and risk factors for LTFU have been described extensively, but rarely in countries of the Central Asia Region (CAR) [3–8]. Only two such studies have been reported from Uzbekistan, a quantitative and qualitative one in Tashkent [9, 10]. The quantitative study found that unemployment, being a pensioner, alcoholism and homelessness were associated with default [10]. Few studies on this subject were reported from other former Soviet Union countries, for example from Latvia, [11] Russia [12, 13], Moldova [14], Estonia [15], Armenia [16] and Georgia [17]. They found a large variety of socio-economic and clinical risk factors to be associated with LTFU.

In Tajikistan, no such study has been reported. Although Tajikistan reported a low proportion LTFU among new and retreatment cases in the last few years (4%) [18], this is considered to be an underestimate. Tajikistan reported 77% multidrug-resistant (MDR) TB

* Correspondence: s.verver@erasmusmc.nl
1 KNCV Tuberculosis Foundation, Evidence team, The Hague, The Netherlands
2 Academic Medical Centre, AIGHD, Amsterdam, the Netherlands
Full list of author information is available at the end of the article.

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Methods
Setting
Tajikistan notified to WHO 7035 TB cases in 2011 and 6508 in 2012, of whom 604 and 694 were confirmed MDR cases. The WHO estimated incidence rate in Tajikistan was 87 per 100,000 in 2016. In 2016 a total of 6232 TB patients were registered for treatment in Tajikistan [19].

Design
We chose a matched case-control design for efficiency, since the proportion of patients LTFU is reported to be only 4%. Patients registered for treatment who became LTFU (as defined by WHO [1]) were defined as cases. Patients diagnosed with TB who did not start treatment are also part of the official WHO definition, but could not be included since they were not registered as such. For each case, two successfully treated (ST) patients following them in the same register were chosen as controls, in effect matching them only on health facility and time of registration (controls had date of registration near that of a case) rather than on the basis of individual characteristics. If any of them was not ST, the next ST patient on the list was chosen as a control.

Study population
The study population consisted only of TB patients registered for first line treatment in 2011 and 2012, who were marked as defaulters (now called LTFU) or successfully treated in the TB registers. In Tajikistan patients who migrated or moved are defined as LTFU, except when further treatment in a different location is confirmed. Therefore migrated and moved patients marked as LTFU were included as cases in the study. It should be noted that patients who move AND report in another clinic for continuation of treatment, were registered as ‘transfer out’ and have been excluded from this study. About 1% of patients had a treatment outcome registered as ‘transfer out’ in 2011.

Sampling method and size
Multistage purposeful sampling was used to maximize the number of LTFU patients found visiting a minimum number of facilities. Patients were selected from TB registers located in regional TB centres. Tajikistan has 5 administrative areas: Sughd, Khatlon, region under republican sub-ordination, Dushanbe and Gorno-Badakhshan Autonomous region (GBAO), with together 59 districts. We selected all districts that each had at least five LTFU DS-TB patients registered for treatment in 2011 [18]. These were 19 districts within 4 administrative areas (only 1 patient LTFU was registered in GBAO in 2011 and this whole region was excluded).

Data collection and validation
Data collection took place in all 34 TB centres between May and June 2014 in the 19 selected districts. Information was taken from TB registers and individual patient records, while facility medical staff were consulted when additional information was needed or when information in registers contradicted patient records. The risk factors measured in the study were those registered in the patient records. Factors such as homelessness and alcoholism had no systematic definition in the patient records, and were based on the observations made by TB clinicians.

An electronic data collection form was developed using the Russian translation of EpiData [20] to obtain information from the TB registers TB03/TB0 3 U, TB01/TB0 1 U. [http://www.who.int/tb/dots/r_and_r_forms/en/], patient records and laboratory registers from TB centres. The tool enabled the direct entry of data extracted from paper documents in an electronic database. To ensure quality, the data entry form was tested in a pilot by two of the researchers, who also participated during the actual data collection to enter data.

Data have been collected by trained study clinicians and epidemiologists in 4 teams of 2 persons each. During the course of data collection the teams held contact via phone in order to solve problems concerning the use of different codes and other queries, ensuring consistency between the teams.

We also asked medical staff (the treating clinician and nurse, whoever knew most about the patient) what was the reason for LTFU according to the health care provider, for each individual patient LTFU.

Data analysis
For data cleaning and analysis the database was exported from EpiData into SPSS 21 for Windows (SPSS, Inc., Chicago, USA). First univariate conditional logistic regressions were run to analyse associations between collected variables and LTFU as dependent variable. Since each case had more than one control the Cox regression
command was used to perform conditional logistic regression. Variables with significant associations in the univariate models were included in a multivariate conditional logistic regression model using the likelihood ratio with backward selection of independent variables. 95% confidence intervals (CI) were calculated for all variables included in the univariate and multivariate regressions.

Permission and informed consent
Official permission to conduct this study was issued by the National Ethics Committee of the Ministry of Health (MoH) Tajikistan, and all facility directors gave permission to participate prior to data collection. Data from TB registers, patient medical records and laboratory registers could only be matched by patient names, which were deleted immediately after linking was completed.

Results
Selection and characteristics of study population
According to the national TB database, 503 patients were LTFU in Tajikistan among the cohorts diagnosed and on first line treatment in 2011 and 2012 [20] (Table 1). This is 4% of the cases notified to WHO whom did not have confirmed MDR (6431 and 5814, respectively). Among them 334 TB patients (64%) were registered in the 19 districts. Two controls were selected per case, therefore 644 ST patients were expected. Only 300 (89.8%) of the expected 334 LTFU patients were actually found in the registers. The others had successful or unclear treatment outcomes or errors in registers such as a missing final sputum test which was not actually missing but just not entered in the register. Only 83.9% of reported LTFU patients could be retrieved from the registers in 2011 and 95.4% in 2012. The 300 LTFU cases have been matched with 644 successfully treated patients (controls) of whom 592 had complete enough data to include them (91.9%).

The majority of ST and LTFU patients in the study population were male (n = 316; 53.4%, n = 202; 67.3% respectively), between 19 and 40 years of age (n = 316; 53.4%, n = 202; 67.3%), living in rural areas (n = 455; 76.9%, n = 236; 78.7%), had PTB (n = 434; 73.3%, n = 253; 84.3%), of which slightly less than half were confirmed smear-positive at baseline (n = 229; 38.7%, n = 140; 46.7%) (Table 2). Only 9.2% of all TB patients registered in 2011 were tested for drug resistance at time of diagnosis.

The majority (69%) of ST patients were smear-negative at end of treatment, the others had unknown smear status. Among those LTFU, the proportion of those who were lost to follow up from TB treatment during the intensive treatment phase (34%) was lower than during the continuation phase (59%), the remainder was unknown.

Factors associated with loss to follow-up
Univariate analysis
The univariate analysis showed that being male (OR = 1.78; 95% CI 1.33–2.40), having side effects (OR = 3.22; CI = 1.64–6.33), being previously treated for TB (OR = 2.86; CI = 1.70–4.82), patient category other (OR = 1.96; CI = 1.27–3.02), having moved within country (OR = 10.7; CI = 4.08–28.1) or migrating out of the country (OR = 9.70; CI = 6.06–15.5), homelessness (OR 2.63, CI = 1.19–5.82) and ever abusing drugs (OR = 5.21; CI = 1.02–26.6) were significantly positively associated with LTFU from treatment (Table 2). The strongest risk factor was moving within or out of country, both as compared to not moving. Forty percent of patients LTFU migrated out of country and 9% within country.

All age groups had a significantly lower risk of LTFU when compared to the largest age group of 19–40 years (Table 2). Other groups who have a lower risk of LTFU were those whose baseline smear was not performed (OR = 0.57; CI = 0.37–0.86), those having EPTB (OR = 0.13; CI = 0.01–1.66), those not being in school (OR = 0.19; CI = 0.13–0.28) or having EPTB (OR = 0.49; CI = 0.34–0.72), those still being in school (OR = 0.45; CI = 0.23–0.89) and pensioners (OR = 0.51; CI = 0.27–0.93).

Other factors not significantly associated with LTFU were rural/urban place of living, seasonal work, alcohol abuse, employment, pregnancy, homelessness and hospitalization during intensive treatment phase (Table 2).

For type of drug-resistance an HIV there were too few patients with test results to do a meaningful analysis.

Multivariate analysis
The factors sex, age group, TB location, side effects, patient category, migration out of Tajikistan, and moved within country were included in the stepwise model for the multivariate analysis. Out of these factors, only having side effects (OR = 3.67; CI = 1.68–8.00), being previously treated (OR = 2.3; CI = 1.05–3.93), moved within country (OR = 11.04; CI = 3.50–34.9)

| Table 1 Selection of patients and those actually found |
|----------------------------------|
| Cases (LTFU) | 2 controls (ST) |
| Registered in national database | | per case |
| 2011 | 2012 | Total |
| Country | DS TB | DS TB | Total |
| 19 Selected Districts with > = 5 patients LTFU | 241 | 262 | 503 |
| (66.8%) | (66.0%) | (66.4%) |
| Found in registers | 135 | 165 | 300 | 592 |
| (83.9%) | (95.4%) | (89.8%) | (91.9%) |
| **Factors**                  | Loss to follow-up | Successful Treated | Crude Odds Ratio | CI (95%)     |
|-----------------------------|-------------------|--------------------|------------------|--------------|
|                             | N     | Column % | N     | Column % |                        |
| Totals                      | 300   | 592      |        |          |                        |
| Sex                         |       |          |        |          |                        |
| Males                       | 202   | 67.3     | 316   | 53.4     | 1.78               | 1.33–2.40           |
| Females                     | 98    | 32.7     | 276   | 46.6     | ref                |                      |
| Age group                   |       |          |        |          |                        |
| 0–18                        | 19    | 6.3      | 83    | 14.0     | 0.36               | 0.21–0.62           |
| 19–40                       | 202   | 67.3     | 316   | 53.4     | ref                |                      |
| 41–60                       | 57    | 19.0     | 136   | 23.0     | 0.68               | 0.47–0.97           |
| >60                         | 21    | 7.0      | 57    | 9.6      | 0.55               | 0.32–0.95           |
| Unknown                     | 1     | 0.3      |        |          |                     |                      |
| Place of Living             |       |          |        |          |                        |
| Rural                       | 236   | 78.7     | 455   | 76.9     | ref                |                      |
| Urban                       | 56    | 18.7     | 132   | 22.3     | 0.59               | 0.29–1.20           |
| Unknown                     | 8     | 2.7      | 5     | 0.8      |                     |                      |
| Baseline smear result       |       |          |        |          |                        |
| Baseline smear negative     | 112   | 37.2     | 212   | 35.8     | ref                |                      |
| Baseline smear positive     | 140   | 46.7     | 229   | 38.7     | 1.15               | 0.83–1.59           |
| Baseline smear not done     | 48    | 16.1     | 150   | 25.3     | 0.57               | 0.37–0.86           |
| Unknown                     | 1     | 0.3      |        |          | ref                |                      |
| Location of TB              |       |          |        |          |                        |
| PTB                         | 253   | 84.3     | 434   | 73.3     | ref                |                      |
| EPTB                        | 47    | 15.7     | 158   | 26.7     | 0.49               | 0.34–0.72           |
| Patient category            |       |          |        |          |                        |
| New                         | 211   | 70.3     | 495   | 83.6     | Ref                |                      |
| Previously treated          | 40    | 13.3     | 34    | 5.7      | 2.86               | 1.70–4.82           |
| Transferred in              | 2     | 0.7      | 4     | 0.7      | 1.39               | 0.20–9.48           |
| Other                       | 47    | 15.7     | 58    | 9.8      | 1.96               | 1.27–3.02           |
| Unknown                     | 1     | 0.3      |        |          | ref                |                      |
| Pregnancy                   |       |          |        |          |                        |
| Pregnancy no                | 75    | 25.0     | 202   | 34.1     | ref                |                      |
| Pregnancy yes               | 3     | 1.0      | 2     | 0.3      | 65.3               | 0 - >100            |
| Pregnancy na.               | 217   | 72.3     | 371   | 62.7     |                     |                      |
| Unknown                     | 5     | 1.7      | 17    | 2.5      |                     |                      |
| Side effects                |       |          |        |          |                        |
| Side effects no             | 237   | 79.0     | 520   | 87.8     | ref                |                      |
| Side effects yes            | 26    | 8.7      | 19    | 3.2      | 3.22               | 1.64–6.33           |
| Unknown                     | 37    | 12.3     | 53    | 9.0      |                     |                      |
| Moved within country        |       |          |        |          |                        |
| Moved no                    | 264   | 88.0     | 570   | 96.3     | ref                |                      |
| Moved yes                   | 26    | 8.7      | 7     | 1.2      | 10.7               | 4.08–28.1           |
| Unknown                     | 10    | 3.3      | 15    | 2.5      |                     |                      |
Table 2 Univariate analyses of factors associated with loss to follow-up (Continued)

| Factor                          | N  | %   | N   | %   | RR  | 95% CI |
|---------------------------------|----|-----|-----|-----|-----|--------|
| **Seasonal work**               |    |     |     |     |     |        |
| Seasonal work no                | 283| 94.3| 568 | 95.9| ref |        |
| Seasonal work yes               | 6  | 2.0 | 11  | 1.9 | 1.02| 0.36–2.90 |
| Unknown                         | 11 | 3.7 | 13  | 2.1 |     |        |
| **Migration other country**     |    |     |     |     |     |        |
| Migration no                    | 167| 55.7| 534 | 90.2| ref |        |
| Migration yes                   | 123| 41.0| 44  | 7.4 | 9.70| 6.06–15.5|
| Unknown                         | 10 | 3.3 | 14  | 2.4 |     |        |
| **Imprisonment ever**           |    |     |     |     |     |        |
| Imprisonment no/unknown         | 292| 96.8| 585 | 98.8| ref |        |
| Imprisonment yes                | 8  | 3.2 | 7   | 1.2 | 2.19| 0.74–6.46|
| **Alcoholism**                  |    |     |     |     |     |        |
| Alcoholism no                   | 247| 82.3| 540 | 91.2| ref |        |
| Alcoholism yes                  | 13 | 4.4 | 14  | 2.4 | 1.87| 0.82–4.28|
| Unknown                         | 40 | 13.3| 38  | 6.4 |     |        |
| **Drug abuse**                  |    |     |     |     |     |        |
| Drug abuse no                   | 253| 84.3| 551 | 93.1| ref |        |
| Drug abuse yes                  | 6  | 2.0 | 3   | 0.5 | 5.21| 1.02–26.6|
| Unknown                         | 41 | 13.7| 38  | 6.4 |     |        |
| **Employment**                  |    |     |     |     |     |        |
| Unemployed                      | 237| 79.0| 364 | 61.5| ref |        |
| Working                         | 17 | 5.7 | 39  | 6.6 | 0.68| 0.36–1.27|
| Student                         | 6  | 2   | 23  | 3.9 | 0.40| 0.16–1.05|
| Pensioner                       | 18 | 6.0 | 55  | 9.3 | 0.51| 0.27–0.93|
| Not applicable                  | 17 | 5.7 | 73  | 12.3|     |        |
| Unknown                         | 5  | 1.7 | 38  | 6.4 |     |        |
| **Education**                   |    |     |     |     |     |        |
| Middle school                   | 249| 83.0| 432 | 73.0| ref |        |
| College                         | 4  | 1.3 | 19  | 3.2 | 0.51| 0.16–1.58|
| University                      | 8  | 2.7 | 16  | 2.7 | 0.84| 0.35–2.04|
| Still studying                  | 11 | 3.7 | 45  | 7.6 | 0.45| 0.23–0.89|
| No degree                       | 11 | 3.7 | 30  | 5.1 | 0.57| 0.26–1.24|
| Unknown                         | 17 | 5.6 | 50  | 8.4 |     |        |
| **Homelessness**                |    |     |     |     |     |        |
| Homelessness no                 | 281| 93.7| 575 | 97.1| ref |        |
| Homelessness yes                | 15 | 5.0 | 15  | 2.5 | 2.63| 1.19–5.82|
| Unknown                         | 4  | 1.3 | 2   | 0.3 |     |        |
| **Hospitalization**             |    |     |     |     |     |        |
| ambulatory                      | 146| 48.7| 292 | 49.3| ref |        |
| hospital                        | 152| 50.7| 296 | 50.0| 1.07| 0.78–1.47|
| Different country                | 1  | 0.3 | 3   | 0.5 | 0.75| 0.08–7.23|
| Prison hospital                 | 1  | 0.3 | 1   | 0.2 | 2.58| 0.16–42.3|

Ref = reference category
and migration to another country (OR = 10.6; CI = 6.12–18.4) had a significant association with LTFU (Table 3). As in the univariate analyses the association was strongest for the factors moved within country and migration to another country, and with slightly higher odds ratios.

Medical staff mentioned a reason for LTFU for 292 out of 317 (92%) patients LTFU. They confirmed that the majority of TB patients was lost to follow-up due to migration to another country (50% of 292) or within Tajikistan (10%), with other reasons mentioned often refusing further treatment (15%), and side effects (8%), stigma (5%) and family problems (5%).

**Discussion**

We found that the main factors associated with LTFU were migration out of country, moving within country, side effects and previous treatment. Medical staff confirmed these but also mentioned patients refusing further treatment, stigma and family problems.

**Treatment phase during LTFU**

LTFU occurred more often in the continuation phase (58.8%) than in the intensive phase of treatment (34.2%). Conversely, an older study (2007) on default in Uzbekistan found that the majority of LTFU cases interrupted treatment in the intensive phase (62%) [10]. At the time of our study, Tajikistan was more advanced in decentralizing services to primary health care facilities than was Uzbekistan; therefore, patients in Tajikistan may have stayed on treatment longer.

**Table 3** Factors associated with loss to follow-up in multivariate analysis

| Factor                     | N  | Adjusted Odds Ratio | CI (95%)  |
|----------------------------|----|---------------------|-----------|
| Side effects               |    |                     |           |
| Side effects no            | 769| ref                 |           |
| Side Effects yes           | 69 | 3.67                | 1.68–8.00 |
| Patient category           |    |                     |           |
| New case                   | 646| ref                 |           |
| Retreatment case           | 96 | 2.03                | 1.05–3.93 |
| Other                      | 94 | 1.65                | 0.89–3.06 |
| Moved within country       |    |                     |           |
| Moved no                   | 808| ref                 |           |
| Moved yes                  | 28 | 11.04               | 3.50–34.9 |
| Migration other country    |    |                     |           |
| Migration no               | 676| ref                 |           |
| Migration yes              | 160| 10.6                | 6.12–18.4 |

*a n = 836, due to exclusion of those with missing values

**Risk factors**

We found the main risk factor for LTFU in Tajikistan was migration to another country. To our knowledge, this has not been reported before, except in Moldova, where spending more than three months abroad within the past year was a risk factor for LTFU. For example a similar study in Uzbekistan did not find this [10]. Many Tajiks migrate to Russia for work. Often when during migration they are diagnosed with TB, they are sent home for treatment. TB treatment in Tajikistan means a substantial drop in financial support for families due to lost wages. Although TB treatment and diagnosis should be free of charge, certain diagnostic procedures and additional medication accompanying TB treatment often have to be paid out of pocket. This is a major burden for patients and their families and increases the motivation to leave the country for work again even if patients have not successfully completed treatment [21].

In contrast to the situation in Central Asia, studies globally found a relationship between being an immigrant coming from another country and LTFU [13, 23–28]. Most of those studies were conducted in European Union (EU) member states or USA where over a third of the reported TB cases are immigrants. In combination with our study, this shows that migration - regardless whether out of or into a country or within a country- may inhibit completion of TB treatment.

For the variable patient category, being previously treated showed a significant positive association with LTFU, as was found elsewhere [14, 15, 17, 26]. This means that patients who already received TB treatment were more likely to be LTFU from subsequent treatments, including patients with a relapse, former treatment failure, after LTFU, and transferred patients.

Our finding that side effects were associated with loss to follow-up, was also found by others [15]. Most studies do not report on an association between LTFU and side effects, possibly since side-effects are often not recorded in a standard way in TB records [4]. An association with LTFU is expected for individuals taking MDR-TB drugs since second line drugs are more toxic and more likely to cause severe side effects.

Many studies have found other factors significantly associated with LTFU, such as alcohol use and drug addiction [12, 14, 16, 22, 29–31]. We could not confirm these, possibly since the factor migration was so strong in our study population. Another reason may be that these factors may not have been noted accurately since alcohol and drug abuse are not socially acceptable in the local culture. Even though every patient diagnosed with TB is tested for HIV as of 2010, many physicians do not note this in the TB registers [32].

Another risk factor that was found to be significant in many other studies but not significant at all in ours was
hospitalization versus ambulatory treatment [10, 30, 33]. Hospitalization during intensive phase is common practice in Tajikistan. Possibly the result of the analysis is related to a clear pre-selection of patients to be hospitalized in Tajikistan since 2011–2012. Alternatively, we may not have measured the actual risk factor, which is: being released from hospitalization to ambulatory care without proper follow-up [10, 30].

Reasons for LTFU given by medical staff
The factors mentioned by the clinical staff, such as stigma, family problems and patient refusing to take more treatment, were within FSU countries also found in Uzbekistan and Armenia [9, 10, 15]. We also attempted in-depth interviews in a later cohort that was LTFU and could interview only 20 of the patients loss to follow-up. Half of those patients still had TB and 6/20 thought they had completed treatment. Although these numbers low, they indicate that there may be communication issues between medical staff and patients on treatment completion.

Strength and limitations
The strength of this study was that it was the first in its kind reported from Tajikistan, and the only recent one from the central Asian region, included a large number of patients and is largely generalizable to the country. A limitation was that only variables available in medical records could be analyzed. Further drug sensitivity testing was not standard yet at time of the study. Lastly, it is possible that answers from medical staff on reasons for LTFU were influenced by recall bias.

Conclusions
In conclusion, we found migration to another country, moving within country, side effects of treatment and previous treatment to be significant risk factors for LTFU. In order to improve follow-up for patients moving within the country it is important to increase the communication and exchange of referral documents between health facilities. A recent meta-analysis showed that psycho-emotional support and socio-economic support were associated with a significant improvement of successful treatment outcomes [34]. Such support may motivate patients to postpone their migration until after treatment completion. Community health workers may assist to reduce LTFU [23]. Expanding international measures such as WHO Europe’s ‘minimum package for cross-border TB control and care’ is crucial in order to improve the situation of TB patients migrating to other countries or those falling sick abroad [35]. Careful monitoring and management of side effects is needed and patients who have been previously treated need extra care to ensure treatment completion.

Endnotes
1The definitions for TB cases and treatment outcomes used in this paper are according to the revised WHO definitions1. However, the study population consists of patients registered in 2011 and 2012 when the new definitions were not yet implemented.

Abbreviations
DS TB: Drug Sensitive Tuberculosis; EPTB: Extra Pulmonary Tuberculosis; HCW: Health Care Worker; LTFU: Loss to follow up; MDR TB: Multi-Drug-Resistant Tuberculosis; MoH: Ministry of Health; PTB: Pulmonary Tuberculosis; ST: Successful Treatment; TB 01 U: Multidrug-Resistant Tuberculosis patient cards; TB 01: Drug Sensitive Tuberculosis patient cards; TB 03 U: Multidrug-Resistant Tuberculosis register; TB 03: Drug Sensitive Tuberculosis register; TB: Tuberculosis; XDR TB: Extensively-Drug-Resistant Tuberculosis

Acknowledgements
We are very grateful to the Ministry of Health, for giving permission for the study, and for staff of the national TB control centre for assisting with data collection. We would like to thank also all medical staff from the participating clinics for hosting the data collectors and assisting to find records and answer questions on inconsistent data.

Funding
This study was funded by the United States Agency for International Development under the USAID Tuberculosis CARE I, Cooperative Agreement No. AID-OAA-A-10-00020.

Availability of data and materials
The datasets used and analysed during the current study is available from the corresponding author on reasonable request.

Authors’ contributions
JW, MM, FS, SA and SV conceived the study during a protocol development workshop. JW, FS and SA collected data. JW and SV analysed and interpreted the data and wrote the first report. CM had a major role in rewriting the report as a paper and doing literature search. All authors contributed to writing the final version of the paper and read and approved the final manuscript.

Authors’ information
JW is currently working at the University of Utrecht, the Netherlands. CM is currently working at the Royal Tropical Institute (KIT), Amsterdam, The Netherlands. SV is currently working at the Department of Public Health, Erasmus MC, Rotterdam, The Netherlands.

Ethics approval and consent to participate
Official permission to conduct this study was issued by the National Ethics Committee of the Ministry of Health (MoH) Tajikistan, and all facility directors gave permission to participate prior to data collection. No individual informed consent was required.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1KNCV Tuberculosis Foundation, Evidence team, The Hague, The Netherlands.
2Department of International Health, University Maastricht, Maastricht, The Netherlands. 3KNCV TB Foundation, country office Tajikistan, Dushanbe, Tajikistan. 4Republican Center for protection of population from TB, Dushanbe, Tajikistan. 5Present address: Royal Tropical Institute (KIT), Amsterdam, The Netherlands. 6Academic Medical Centre, AIGHD,
Amsterdam, the Netherlands. Present address: Department of Public Health, Erasmus MC, Rotterdam, The Netherlands.

Received: 5 November 2016 Accepted: 31 July 2017
Published online: 04 August 2017

References

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: WHO; 2013.
2. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis. 2010;14(4):382–90.
3. do Brasil PEAA, Braga J. Meta-analysis of factors related to health services that predict treatment default by tuberculosis patients. Cad Saúde Pública. 2008;A:485–502.
4. Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDRTB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(9):969–78.
5. Kruk ME, Schwalbe NR, Aquir CA. Timing of default from tuberculosis treatment: a systematic review. Tropical Med Int Health. 2008;13(5):703–12.
6. Castelnuovo B. A review of compliance to anti tuberculosis treatment and risk factors for defaulting in sub Saharan Africa. Afr Health Sci. 2010;10(3):20–4.
7. Tola HH, Tol A, Shoaiezadeh D, Garmaroudi G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. Iran J Public Health. 2015;44(1):1–11.
8. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e26914.
9. Hasker E, Khodjikhanoz M, Sayidinova S, Rasulova U, Uzakova G, Butakobo L, Veen J, van der Werf MJ, Lefevre P. Why do tuberculosis patients default in Tashkent City, Uzbekistan? A qualitative study. Int J Tuberc Lung Dis. 2010;14(9):1132–9.
10. Hasker E, Khodjikhanoz M, Usarova S, Aramidinov U, Yuldashova U, van der Werf MJ, Uzakova G, Veen J. Default from tuberculosis treatment in Tashkent, Uzbekistan: who are these defaulters and why do they default? BMC Infect Dis. 2008;8:97.
11. Leimane V, Rekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Lasenok K, Wells C. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia in a retrospective cohort study. Lancet. 2005;365(9456):318–26.
12. Gelmanova IY, Khasiev Sh, Golubchikova VT, Bezenez VI, Strels AK, Yanova GV, Atwood S, Murray M. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ. 2007;85(9):703–11.
13. Jakuboviček WM, Bogorodskaya EM, Borisov ES, Danilova DI, Altraja A. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis. 2007;11(1):46–53.
14. Jenkins HE, Ciobanu A, Plecas V, Crudu V, Galusca I, Soltan V, Cohen T. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. Int J Tuberc Lung Dis. 2013;17(3):373–80.
15. Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14(4):544–63.
16. Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F, Bastard M, Bonnet M. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study. Int J Tuberc Lung Dis. 2014;18(2):160–7.
17. Kuchukhidze G, Kumar AM, de Colombani P, Khogali M, Nanava U, Blumberg HM, Kemper RR. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action. 2014;4(Suppl 2):541–6.
18. Tajikistan National Tuberculosis Program. Numbers of defaulters in all oblasts and districts of Tajikistan. Dushanbe: Tajikistan National Tuberculosis Program; 2013.
19. World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13. Geneva: WHO; 2016.
20. Epidata. Epidata Software (DK) [Internet]. 2001 [cited 2015 Jun 03]. Available from: http://www.epidata.dk.
21. Gilpin C, de Colombani P, Hasanova S, Sirojdjidinova U. Exploring TB-related knowledge, attitude, behaviour, and practice among migrant workers in Tajikistan. Tuberc Res Treat. 2011;2011:1–10.
22. Kurbatova EV, Taylor A, Garmmino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio M, Riekstina V, Vildepp P, Zignol M, Cegelski JP. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTs-plus projects. Tuberc. (Edinb). 2016;92(5):397–403.
23. Toczek A, Cox H, Du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299–307.
24. Babalik A, Kiliaraslan Z, Sevkani Caner S, Gunor G, Gonenec Ortakaylu M, Gencer S, McCurdy SA. A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul. Turkey Jpn J Infect Dis. 2013;66(2):113–20.
25. Borgdorff MW, Veen J, Kalisvaart NA, Broekmans JM, Nagelkerke NID. Defaulting from tuberculosis treatment in the Netherlands: rates, risk factors and trend in the period from 1993–1997. Eur Respir J. 2000;16(2):209–13.
26. Cayla JA, Rodrigo T, Ruiz-Manzano J, Caminero JA, Vidal R, Garcia JM, Blanquer R, Casals M. Tuberculosis treatment adherence and fatality in Spain. Respir Res. 2009;10:121.
27. Cegolon L, Maguei H, Mastangrello G, Carless J, Kruijshaar ME, Verlander NQ. Predictors of failure to complete tuberculosis treatment in London, 2003–2006. Int J Tuberc Lung Dis. 2010;14(11):1411–7.
28. Conwell DS, Mosher A, Khan A, Tapy J, Sandman L, Vernon A, Horsburgh CR. Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC study 22). Contemp Clin Trials. 2007;28(3):288–94.
29. Dixel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a survey. 1997–2001. Int J Tuberc Lung Dis. 2003;7(10):124–31.
30. Finl N, Hejblum G, Borget I, Mallet HP, Antoun F, Che D, Chouaid C. Management and treatment outcomes of tuberculosis patients, eastern Paris, France, 2004. Int J Tuberc Lung Dis. 2009;13(7):881–7.
31. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax. 2007;62(8):667–71.
32. Tajikistan National Tuberculosis Program. Documentation of HIV coinfection and other sensitive patient information. Dushanbe: Tajikistan National Tuberculosis Program; 2014.
33. Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK. Loss-to-follow-up on multidrug resistant tuberculosis treatment in Gujarat, India: the when and who of it. PLoS One. 2015;10(7):1–10.
34. van Hoorn R, Jarrimillo E, Collins D, Gebhard A, van den Hof S. The effects of psycho-emotional and socio-economic support for tuberculosis patients on treatment adherence and treatment outcomes – a systematic review and meta-analysis. PLoS One. 2015;11(4):e0154095.
35. Dara M, De Colombani P, Petrova-Benedict R, Centis R, Zellweger JP, Sandgren A, Heldal E, Sotgiu G, Jansen N, Bahtijarevic R, Migliori GB. Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J. 2012;40(5):1081–90.